SEATTLE, June 01, 2021, (MEDGADGET) — Overview
Rabies is a viral zoonotic disease spread through dog bites that causes irreversible and lethal brain and spinal cord inflammation. Furious rabies and paralytic rabies are the two forms of rabies. Hyperactivity and hallucination are two signs of furious rabies. Rabies that causes paralysis and coma is known as paralytic rabies. Rabies tends to be a deadly illness, and it can be managed by vaccines and drugs that have been used for a long time to prevent rabies death. For instance, according to the World Health Organization (WHO), rabies affects around 10,000 individuals globally each year, with dog bites accounting for over 99% of cases. Wounds, fever and discomfort at the wound, tingling, and pricking at the wound site are all symptoms of rabies, which may lead to cardiac or respiratory arrest if not treated properly. Moreover, according to the World Health Organization (WHO), rabies took the lives over 59,000 people in 150 countries in 2017, with around 95 percent of cases happening in rural areas.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-pdf/4005
Impact of COVID-19 Analysis on the Global Rabies Vaccine Market
COVID-19’s effect on the worldwide, moreover rabies vaccine market has had a significant impact on every market around the world. Any economy will take a long time to regain its losses as the world begins to recover from the COVID-19 situation. Owing to social distancing, people have been unable to contact their doctors for vaccinations. According to the present situation, COVID-19 has had a huge impact on potential demand prospects, sales growth graphs, and corporate benefit increases in the global rabies vaccine market.
Major market players are concentrating on research and development initiatives which are expected to propel growth of the global rabies vaccine market over the forecast period. For instance, in 2017, CPL Laboratories (India), a joint venture biotechnology company established in 2009 by Novavax Inc., USA and Cadila Pharmaceuticals Limited, stated that Nano- particle vaccine of baculvirous-derived glycoprotein, a four dose regime vaccine is in phase-3 human trial, and is expected to be approved by 2021.
Rabies was almost unknown in the U.S. from the early 1960s to 2000, when it suddenly increased to over 100 cases a year. Despite the rarity of deaths, the lack of knowledge about rabies is proving to be a concern. Between 1960 and 2018, around 127 cases of rabies were recorded in the United States as a result of dog and bat bites. Moreover in Asia, rabies is a significant cause of death in India, accounting for around 35,000 deaths. Rabies is responsible for over 55 percent of all deaths. Africa pays little on post-exposure prophylaxis treatment of rabies and has the largest mortality rate due to rabies, with an estimated 21,476 human deaths due to dog bite rabies. However, annually, 1875 and around 229 deaths are estimated in Central Asia and Middle East Asia, respectively. These factors are is expected to propel the global rabies vaccines market growth over the forecast period.
Due to a lack of understanding and the high cost of vaccination, emerging countries in Africa and Asia are expected to hamper growth of the global rabies vaccine market. Prophylaxis is a post-exposure dosage regimen for dog-mediated rabies. For instance, according to the World Health Organization (WHO), the average expense of PEP in 2017 was around US$ 1.5 million, rendering it unaffordable in low- and middle-income countries and hindering the global rabies vaccine market’s growth over the forecast period.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/4005
The global rabies vaccine market is segmented into North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. Over the forecast period, North America is expected to have the highest share of the global rabies vaccines market. Increasing government investments in the public sector, as well as rabies-eradication projects, are expected to pose attractive growth in the region. For instance, in 2008, countries in North America developed the North America Rabies Management Plan, which assessed and defined the needs and goals for controlling rabies in Canada, Mexico, and the U.S.
Furthermore, in 2014, according to the European Centre for Disease Prevention and Control, although three cases of rabies were registered in Europe, despite the fact that Europe is the world’s leading rabies vaccine producer. GlaxoSmithKline, Sanofi–Pasteur, and Novartis AG are the main market players in Europe.
Moreover, Asia Pacific is expected to witness a significant growth over the forecast period due to active participation by major manufacturers in Asia Pacific countries such as Japan, China, and India in the production of novel rabies vaccines and replacements. For instance, in February 2018, BioNote, Inc., Vcheck, a modern immune-fluorescent technology developed by a South Korean veterinary diagnostic company specializing in rabies diagnostics, will calculate diagnostic outcome values using fluorescent materials that aid in the detection of zoonotic disease in animals.
Due to the burden of rabies, the Asia Pacific industry is expected to register new competitors and is a highly competitive market. For instance, in 2017, according to data published by the World Health Organization (WHO), India is responsible around 59.9% of Asian rabies deaths and over 35% of global rabies deaths. Yisheng Biopharma, Serum Institute of India, Zuventus, and Bharat Biotech Ltd are some of the big players in the field. Furthermore, vaccine candidates are in clinical trials at Yisheng Laboratories and CPL Laboratories (both in India).
To get detailed table of content (ToC), please click – https://www.coherentmarketinsights.com/ongoing-insight/toc/4005
Major players are dominating in global rabies vaccine market are Novartis International AG, Sanofi S.A., Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd, Bharat Biotech Ltd, Cpl Biologicals Private Limited, Zuventus HealthCare Ltd., Yisheng Biopharma Co., Ltd, Chiron Behring Vaccines Private Limited, GlaxoSmithKline plc, and Bavarian Nordic A/S.
- The World Organization for Animal Health (OIE), a vaccine bank, was established in 2012 with production order for rabies vaccine of 50,000 doses on December 31, 2016. The OIE recorded 16 million doses of vaccines in 24 countries for pre- and post-exposure prophylaxis treatment for rabies.
- In 2016, Serum Institute of India, developed new rabies vaccine, RABIVAS-S, for countries with highest burden of rabies.
- In 2019, GlaxoSmithKline divested its rabies and tick-borne vaccine to Bavarian Nordic, and incurred payment of US$ 36 million from Bavarian Nordic.
- In 2019, Yisheng Biopharma (Singapore) Pte Ltd stated that development of adjuvant rabies vaccine, PIKA which is composed of RABIPUR and polyisonic-polycytidcyclic acid, has completed its phase 2 clinical trial.
- In 2019, Asian subsidiary of GlaxoSmithKline divested its Chiron Behring Vaccines unit in Gujarat, India to domestic clinical biotechnology company, Bharat Biotech.
- In June 18, 2020 Bavarian Nordic A/S and Valneva SE announced a partnership for marketing and distribution of rabies and tick-borne vaccines in selected European countries and Canada.
- In 2019, Wuhan Institute of Virology announced positive results of a novel rabies vaccine in pre-clinical test. The novel vaccine is a live attenuated vaccine; VEEV-RABV-G.
By Vaccine Type-
- Neutral vaccine
- Suckling mouse brain vaccine
- Semble rabies vaccine
- Non–neutral vaccine
- Duck embryo vaccine
- Cell culture vaccine
- Human diploid cell vaccine (HDCV)
- Purified chick embryo cell vaccine (PCECV)
- Purified Vero cell rabies vaccine (PVRV)
- Primary hamster kidney cell vaccine (PHKCV)
By Route of Administration-
- Intra-muscular vaccine
- Oral vaccine (Veterinary use)
- Vaccination Centers
- North America
- Latin America
- Asia Pacific
- Middle East
Other Related News:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027